According to FutureWise analysis the market for Carfilzomib in 2023 is US$ 0.2 billion, and is expected to reach US$ 0.25 billion by 2031 at a CAGR of 2.80%

Carfilzomib, marketed under the trade name Kyprolis, is an anti-cancer medication derived from the naturally occurring compound epoxomicin. It is notable for its ability to bind to the 20-S proteasome and inhibit chymotrypsin activity, making it an effective treatment for blood cancers, particularly multiple myeloma. Carfilzomib is typically administered in combination with other medications such as lenalidomide or dexamethasone to enhance its therapeutic effects.

One of the significant advantages of Carfilzomib is its increased efficacy compared to traditional cancer therapies, along with a relatively favorable side effect profile. However, some patients may experience side effects such as severe bloating, blood in the urine, chest pain, nausea, diarrhea, muscle pain, and headaches. While most side effects can alleviate within a few weeks, it is essential for patients to be monitored throughout their treatment.

Carfilzomib is available in varying dosages, with a 10 mg injection being the most potent and a 60 mg injection the strongest. This medication exhibits high selectivity for the N-terminal and threonine active sites within the proteasome. In preclinical studies, Carfilzomib has demonstrated safety when administered on consecutive days and has shown effectiveness against solid tumors, lymphomas, and myeloma, especially in patients who have developed resistance to bortezomib, another proteasome inhibitor.

Manufactured by Novartis International AG, Carfilzomib is primarily used in specialized drug centers for patients with multiple myeloma and non-Hodgkin lymphoma. Research is ongoing to explore its potential applications against other cancers, including lung, bladder, gastric, and ovarian cancers.

As a member of the proteasome inhibitors class, Carfilzomib works by blocking specific enzymes necessary for cell growth, preventing proteins from attaching to DNA, and consequently affecting cell division and survival. This mechanism aids in reducing tumor size and improving the quality of life for multiple myeloma patients. Carfilzomib can be administered in a single dose and is often paired with dexamethasone to treat various hematological malignancies such as relapsed/refractory acute lymphoblastic and chronic leukemias, as well as other blood cancers.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=15185&type=requestsample

 

 

 

Carotenoids Market Segmentation:

By Type

  • 10mg Injection
  • 30mg Injection
  • 60mg Injection

 

By Application

  • Hospitals
  • Drug Centers
  • Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

 

Competitive Landscape in Carotenoids Market:

  • Cayman Chemical
  • Tecoland Corporation
  • Shanghai Chiral Chemicals
  • Vijayasri Organics Ltd
  • Amgen Inc
  • Gyma Laboratories of America
  • Hangzhou Longshine BioTech Co Ltd
  • Active Peptide
  • Natco
  • AstraZeneca

 

Buy now the latest version of this report:

https://www.futurewiseresearch.com/checkout.aspx?ReportId=15185&license=multi

 

**Objectives of this Study: **

  1. To provide a comprehensive analysis of the Carotenoids Market By Type, By Application and By Region.
  2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
  3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
  4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                
Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
  • The customization services offered are free of charge with the purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com